Navigating the Pharmacist Vaccine Reimbursement Paradox

Pharmacists are currently recognized as some of the most accessible health care providers in the world, yet a recent systematic review published in Exploratory Research in Clinical and Social Pharmacy confirms that their full potential as immunizers remains stifled by a complex web of financial and regulatory barriers.¹

“Since [COVID-19], pharmacies have willingly taken on the load of providing vaccines to their communities. Pharmacies are positioned to be a prime location for patients to receive services like this,” Jennifer Griffin, PharmD, MS, clinical pharmacist at Harps Food Stores, Inc, told Drug Topics. “If pharmacies can streamline administering and billing vaccines into their workflow, it’s not a burden; it’s a significant revenue source. In some states, pharmacists can medically bill for vaccine administration and vaccine counseling services, providing additional revenue from offering this service to patients.”

Although the scope of pharmacy practice has evolved from a product-oriented role to a direct public health provider, the infrastructure for billing and reimbursement has failed to keep pace nationwide. According to the authors of the study, the most significant obstacles to expanding these services fall within the outer domain of health care, specifically regarding the lack of standardized reimbursement models and inadequate remuneration for the time and expertise required to administer vaccines.¹

The financial challenge is further complicated by a startling implementation gap in the US. Even in states that have enacted provider status laws intended to allow pharmacists to bill medical benefits rather than just prescription drug benefits, research shows that pharmacists are almost never submitting these health services claims.²

“From my perspective of working in a pharmacy that is well-seasoned in medical billing, I see opportunities instead of challenges,” continued Griffin. “The only challenge I see is for the pharmacies who do not get on board with these medical billing practices and get left behind.”

According to a Journal of the American Pharmacists Association claims analysis, it was revealed that only 0.4% of pharmacy vaccination visits included outpatient service claims, suggesting that the mere existence of a law does not guarantee a functional payment pathway. This disconnect is largely attributed to payers who are not yet prepared to support these claims, onerous credentialing processes, and a fragmented landscape of state-specific billing codes that make scaling services difficult for busy pharmacy teams.

Beyond legislative hurdles, the actual rates of reimbursement vary widely across state lines, creating a patchwork of regional rules that can threaten the financial viability of a vaccination program.³

In many regions, Medicaid programs reimburse at rates significantly below Medicare or private sector benchmarks, sometimes providing less than 85% of the private sector price for the vaccine product itself. Although Medicare Part B offers more consistency, its payment rates are geographically adjusted, meaning the administration fee a pharmacy receives can fluctuate based on its specific zip code.

This variability forces many pharmacies to evaluate the feasibility of stocking certain vaccines on a case-by-case basis, which ultimately creates barriers for patient access.

The legal authority to vaccinate also adds a layer of operational complexity, as every state has different details regarding age limitations and the necessity of a patient-specific prescription. Although some states allow pharmacists to prescribe vaccines independently, others require restrictive prescriber-approved protocols that add to the administrative burden.⁴

This burden is expected to grow as clinical guidelines stemming from federal health programming shift toward shared clinical decision-making for certain pediatric and high-risk vaccines. This shift moves away from routine, population-based recommendations toward individualized risk assessments, which increases the time required for counseling and documentation without a corresponding increase in reimbursement.⁵

Ultimately, the successful expansion of pharmacist-led vaccination services is inextricably linked to legislative reform and a reorganized reimbursement structure. Without standardized compensation that accounts for both the clinical product and the professional service, the financial pressures on community pharmacies may lead to closures or a reduction in available public health services.

To move forward, industry experts advocate for a unified approach involving policy makers and payers to simplify credentialing and ensure that pharmacists are fairly compensated for their essential role on the patient care team. As government-related pressures further stunt overall vaccine administration, pharmacists’ ability to bill for vaccine services does not look like it will be improved on a federal level anytime soon.

However, in the meantime, from some perspectives like Griffin’s, pharmacists should be proactive in homing in on their vaccination strategies instead of waiting on federal reform to make a true change in the health care system—while she also believes vaccine billing will continue to improve across states.

“As payers begin to see the full capability and impact of community pharmacists, the opportunities to medical bill for vaccine services will continue to grow,” she concluded. “As pharmacists, we frequently have consultations with patients on what vaccines they are eligible for, and we make recommendations. That should be a payable service that pharmacists bill for, and these opportunities are making their way across the United States.”

REFERENCES

1. Abdulselam M, El-Awaisi A, Nasr ZG, Shaar S, El Hajj MS. Barriers and facilitators for pharmacist-led vaccination services: a systematic review using the Consolidated Framework for Implementation Research (CFIR). Explor Res Clin Soc Pharm. 2025;21:100687. doi:10.1016/j.rcsop.2025.100687

2. Wittenauer R, Bacci JL, Shah PD, Stergachis A. Vaccination payments in states with provider status for pharmacists: a claims analysis. J Am Pharm Assoc (2003). 2024;65(1):102301. doi:10.1016/j.japh.2024.102301

3. State-by-state vaccine reimbursement: what pharmacies need to know. DocStation. December 4, 2025. Accessed February 19, 2026. https://docstation.co/blog/state-by-state-vaccine-reimbursement-what-pharmacies-need-to-know

4. Pharmacist administered vaccines. National Alliance of State Pharmacy Associations. Updated June 2022. Accessed February 19, 2026. https://naspa.us/wp-content/uploads/2022/06/Pharmacist-Immunization-Authority-June-2022.pdf

5. Goad J, Halpern L. Pharmacists face new challenges under updated HHS vaccine guidance. Pharmacy Times. January 13, 2026. Accessed February 19, 2026. https://www.pharmacytimes.com/view/pharmacists-face-new-challenges-under-updated-hhs-vaccine-guidance